"Cùng Sống Khỏe” 2026-2030: Advancing collaboration for the health of Vietnamese people

The partnership reaffirms Novartis Vietnam’s commitment to supporting national healthcare priorities through initiatives focused on healthcare development, digital health, and equitable access to medical services, contributing to a more sustainable and inclusive healthcare system.

Under the MoU, the collaboration will focus on four key areas, including supporting scientific exchange and the development of professional medical guidelines; strengthening clinical care capacity and community health; advancing technology, scientific research, and international cooperation; and supporting monitoring and evaluation activities to measure the impact of healthcare interventions and related programs.

The agreement also aims to support healthcare practitioners through medical training programs, scientific exchange initiatives, and updated treatment knowledge, while promoting healthier lifestyles and disease prevention efforts at the community level.

In Vietnam, Novartis has implemented the "Cùng Sống Khỏe" ("Live Healthy Together") program since 2012. Over the past 13 years, the initiative has expanded across dozens of provinces and cities, providing health education and communication on hypertension, diabetes, and cardiovascular diseases to more than two million community members.

The program has also contributed to strengthening non-communicable disease management capacity at nearly 400 commune-level health stations nationwide. According to data recorded between 2024 and 2025, hypertension control rates in participating areas improved from 32% to 67%, while diabetes control rates increased from 27% to 79%.

The new 2026–2030 MoU marks a strategic shift from traditional collaboration toward a more sustainable, system-level approach with measurable impact. The partnership aims to improve treatment outcomes, reduce disease burden, and enhance overall healthcare system efficiency in Vietnam.

Dr. Ha Anh Duc, Director of the Department of Medical Examination and Treatment Management, Ministry of Health said Vietnam’s National Target Program on Health Care, Population and Development for the 2026–2035 period prioritizes primary healthcare and health digitalization.

"The support provided by organizations such as Novartis plays an important role in helping achieve these goals, particularly in underserved areas," he said. "This MoU reaffirms the important role of public-private collaboration in strengthening the healthcare system for the benefit of the Vietnamese people."

Speaking at the signing ceremony, Mr. Jondy Syjuco, Country President of Novartis Vietnam, said science only creates meaningful impact when it reaches patients and communities.

"Thirteen years of implementing the ‘Cùng Sống Khỏe’ program reflects our long-term commitment to improving community health in Vietnam," he said. "The MoU enables us to deepen collaboration with our partners, contribute to national healthcare priorities, and help build a more effective, patient-centered healthcare system."

The "Cùng Sống Khỏe" program is part of Novartis’s global community health strategy. In April 2026, the company announced plans to expand its cardiovascular disease and cancer-focused community programs from 11 countries to more than 30 countries by 2030, with the goal of improving healthcare access for low-income, rural, and underserved populations.